Literature DB >> 27681157

Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.

Ugur Eskiocak, Vijayashree Ramesh, Jennifer G Gill, Zhiyu Zhao, Stacy W Yuan, Meng Wang, Travis Vandergriff, Mark Shackleton, Elsa Quintana, Arthur E Frankel, Timothy M Johnson, Ralph J DeBerardinis, Sean J Morrison.   

Abstract

Entities:  

Year:  2016        PMID: 27681157      PMCID: PMC5056410          DOI: 10.1038/ncomms13080

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


× No keyword cloud information.
. Arthur E. Frankel, who helped to interpret the clinical relevance of the findings, was inadvertently omitted from the authors list during the final stages of production. This has now been corrected in both the PDF and HTML versions of the Article.
  2 in total

1.  Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.

Authors:  Arthur E Frankel; Ugur Eskiocak; Jennifer G Gill; Stacy Yuan; Vijayashree Ramesh; Thomas W Froehlich; Chul Ahn; Sean J Morrison
Journal:  Neoplasia       Date:  2017-03-06       Impact factor: 5.715

2.  MOFs-based nanoagent enables dual mitochondrial damage in synergistic antitumor therapy via oxidative stress and calcium overload.

Authors:  Weier Bao; Ming Liu; Jiaqi Meng; Siyuan Liu; Shuang Wang; Rongrong Jia; Yugang Wang; Guanghui Ma; Wei Wei; Zhiyuan Tian
Journal:  Nat Commun       Date:  2021-11-04       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.